Earnings History Data for Summit Therapeutics Inc. (SMMT) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Summit Therapeutics Inc.
Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20-02-2024 | PM | SMMT | Summit Therapeutics Inc. | 3,270 | -0.05 | 0.00 | -0.07 | Summit Therapeutics Non-GAAP EPS of -$0.04 [2/20/2024 7:07 AM] |
3.73 | -1.34 (-26.43%) |
4.87 | -0.20 (-3.94%) |
1.25 - 5.14 | 5,948,103 | 1,950,000 | 21,495 | ||
| 07-11-2023 | PM | SMMT | Summit Therapeutics Inc. | 1,400 | -0.03 | 0.00 | -0.14 | Summit Therapeutics GAAP EPS of -$0.09 [11/7/2023 7:14 AM] |
1.93 | -0.26 (-11.70%) |
2.17 | -0.01 (-0.46%) |
0.66 - 5.78 | 1,470,409 | 910,000 | 24,941 | ||
| 09-08-2023 | PM | SMMT | Summit Therapeutics Inc. | 1,240 | -0.02 | 0.00 | -0.17 | Summit Therapeutics GAAP EPS of -$0.02 [8/9/2023 7:17 AM] |
1.93 | 0.18 (10.00%) |
1.81 | 0.06 (3.43%) |
0.66 - 5.78 | 1,588,355 | 1,080,000 | 24,798 | ||
| 11-05-2023 | PM | Before the open (May 11) |
SMMT | Summit Therapeutics Inc. | 159.47 | -0.06 | 0.00 | -0.22 | Summit Therapeutics GAAP EPS of -$1.43 [5/11/2023 7:31 AM] |
1.93 | -0.20 (-9.20%) |
2.19 | 0.07 (3.30%) |
0.66 - 5.78 | 1,767,250 | 1,990,000 | 56,115 | |
| 11-08-2022 | PM | SMMT | Summit Therapeutics Inc. | 87.96 | -0.17 | 0.00 | -0.27 | Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M [8/11/2022 8:56 AM] |
1.09 | 0.05 (4.81%) |
1.06 | 0.02 (1.92%) |
0.88 - 8.38 | 67,607 | 130,000 | 400 | ||
| 17-03-2022 | AH | SMMT | Summit Therapeutics Inc. | 228.52 | -0.28 | 0.00 | -0.18 | Summit Therapeutics GAAP EPS of -$0.28, revenue of $0.25M [3/17/2022 5:01 PM] |
3.16 | 0.03 (0.96%) |
3.00 | -0.13 (-4.15%) |
1.88 - 8.70 | 131,560 | 198,236 | 2,163 | ||
| 11-08-2021 | PM | SMMT | Summit Therapeutics Plc | 784.00 | -0.27 | -0.18 | 0.00 | Summit Therapeutics reports Q2 results [8/11/2021 8:28 AM] |
7.78 | -0.32 (-3.95%) |
8.15 | 0.05 (0.62%) |
3.14 - 12.30 | 166,878 | 110,000 | 123 | ||